230 related articles for article (PubMed ID: 32302707)
1. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Casillo GM; Mansour AA; Raucci F; Saviano A; Mascolo N; Iqbal AJ; Maione F
Pharmacol Res; 2020 Jun; 156():104791. PubMed ID: 32302707
[TBL] [Abstract][Full Text] [Related]
2. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
3. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
4. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
Georgiev T
Rheumatol Int; 2020 May; 40(5):825-826. PubMed ID: 32232552
[No Abstract] [Full Text] [Related]
5. Immunomodulation in COVID-19.
Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
[No Abstract] [Full Text] [Related]
6. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
7. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
8. Potential role of anti-interleukin-17 in COVID-19 treatment.
Ayhan E; Öztürk M; An İ; Abdelmaksoud A; Araç E
Dermatol Ther; 2020 Jul; 33(4):e13715. PubMed ID: 32475041
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2: a time for clear and immediate action.
Poland GA
Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
[No Abstract] [Full Text] [Related]
10. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Abdulrab S; Al-Maweri S; Halboub E
Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
[No Abstract] [Full Text] [Related]
11. Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.
Cafarotti S
J Thorac Oncol; 2020 Jul; 15(7):e101-e103. PubMed ID: 32353597
[TBL] [Abstract][Full Text] [Related]
12. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
13. [Not Available].
Balavoine JF
Rev Med Suisse; 2020 May; 16(695):1126. PubMed ID: 32462848
[No Abstract] [Full Text] [Related]
14. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Spinelli FR; Conti F; Gadina M
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
[TBL] [Abstract][Full Text] [Related]
15. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
16. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs.
Isaacs JD; Burmester GR
Ann Rheum Dis; 2020 Aug; 79(8):991-993. PubMed ID: 32527869
[No Abstract] [Full Text] [Related]
17. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
Regidor PA
Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
[No Abstract] [Full Text] [Related]
18. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
Deftereos S; Giannopoulos G; Vrachatis DA; Siasos G; Giotaki SG; Cleman M; Dangas G; Stefanadis C
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):255. PubMed ID: 32337546
[No Abstract] [Full Text] [Related]
19. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Feldmann M; Maini RN; Woody JN; Holgate ST; Winter G; Rowland M; Richards D; Hussell T
Lancet; 2020 May; 395(10234):1407-1409. PubMed ID: 32278362
[No Abstract] [Full Text] [Related]
20. Audio Interview: Capitalizing on Immune Responses to Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
[No Abstract] [Full Text] [Related]
[Next] [New Search]